

**BILL SUMMARY**  
2<sup>nd</sup> Session of the 57<sup>th</sup> Legislature

<b>Bill No.:</b>	<b>SB 1598</b>
<b>Version:</b>	<b>Engrossed</b>
<b>Request Number:</b>	
<b>Author:</b>	<b>Rosino (S), Hill (H)</b>
<b>Date:</b>	<b>4/30/2020</b>
<b>Impact:</b>	<b>Please see previous summary of this measure</b>

**Research Analysis**

SB 1598 requires health plans to provide coverage for testing for certain pediatric autoimmune neuropsychiatric disorders if the patient:

- Presents neuropsychiatric symptoms that do not improve with treatment within 45 days, or
- Has been diagnosed with an infection or illness within five years and testing has been ordered by a health provider.

Coverage for testing is limited to one test per year with a maximum allowance of \$1,000. Testing may not be subject to any applicable cost-sharing responsibilities. Insurers may utilize prior authorization mechanisms for testing. Lastly, the measure allows for the sunset of the measure if auto-antibody and calcium calmodulin dependent protein Kinase II cell-based testing is not recognized by the American Academy of Pediatrics within five years.

Prepared By: Anna Rouw

**Fiscal Analysis**

The measure is currently under review and impact information will be completed.

Prepared By: Mark Tygret

**Other Considerations**

None.